Automated glycan assembly was developed as a rapid method to access complex carbohydrates that were previously not attainable. In 2002 Ancora Pharmaceuticals was established to capitalise on the early methodological advances to carbohydrate chemistry and sold to Corden Pharma in 2013.
Following more than twelve years optimising all aspects of automated glycan assembly, the Glyconeer 2.1, the first commercial glycan synthesiser was developed in 2014 by GlycoUniverse
that also offers carbohydrate building blocks to fuel the instrument and provides custom synthesis services.
Rapid access to defined carbohydrate antigens allowed for a medicinal chemistry approach to vaccine development. A series of semi-synthetic glycoconjugate vaccine candidates was developed to prevent bacterial infections with Streptococcus pneumoniae
as well as hospital acquired infections such as Cöostridium difficile and others. An extensive patent portfolio was licensed by Vaxxilon AG
that is currently advancing a series of vaccine candidates into the clinic.
Continuous chemistry has proven powerful to produce active pharmaceutical ingredients on large scale. In particular photochemical processes that were rarely used previously have benefited from the flow regime. ArtemiFlow GmbH
is applying continuous processes to produce